English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients

Inyama Asuquo, M., Effa, E., Otu, A., Ita, O., Udoh, U., Umoh, V., et al. (2020). Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients. 2020.07.02.20145441.

Item is

Files

show Files
hide Files
:
MedRxiv 2020 Asuquo.pdf (Preprint), 325KB
Name:
MedRxiv 2020 Asuquo.pdf
Description:
-
OA-Status:
Not specified
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
Under a creative common license

Locators

show

Creators

show
hide
 Creators:
Inyama Asuquo, Marcus1, Author
Effa, Emmanuel1, Author
Otu, Akaninyene1, Author
Ita, Okokon1, Author
Udoh, Ubong1, Author
Umoh, Victor1, Author
Gbotosho, Oluwabukola1, Author
Ikpeme, Anthonia1, Author
Ameh, Soter1, Author
Egbe, William1, Author
Etok, Margaret1, Author
Guck, Jochen2, 3, 4, Author           
Ekpenyong, Andrew1, Author
Affiliations:
1External, ou_persistent22              
2Guck Division, Max Planck Institute for the Science of Light, Max Planck Society, ou_3164416              
3Max-Planck-Zentrum für Physik und Medizin, Max Planck Institute for the Science of Light, Max Planck Society, ou_3164414              
4Friedrich-Alexander-Unversität Erlangen-Nürnberg (FAU), Dept. of Physics, Erlangen, Germany, ou_persistent22              

Content

show
hide
Free keywords: -
 Abstract: The coronavirus disease 2019 (COVID-19) is now a pandemic with devastating social and economic consequences. The extent of the spread of COVID-19 within populations is uncertain since diagnostic tests have not been carried out on all eligible persons and doing such diagnostic tests on everyone is much less feasible in developing countries such as Nigeria. Tests for antibodies to SARS-CoV-2, the virus that causes COVID-19, are more affordable, readily available, and require minimal training than current diagnostic tests. Employing a seroepidemiological strategy, serological tests were conducted on 66 volunteering staff and patients at the University of Calabar Teaching Hospital (UCTH), a Federal Government owned tertiary healthcare facility, to determine the extent of exposure to SARS-CoV-2, from 17th to 25th June 2020. Using a COVID-19 IgG/IgM Rapid Test Cassette with emergency use authorization (EUA) from the Food and Drug Administration (FDA) of the United States, it was observed that of the 66 samples tested, 5 (7.6%) were both IgG and IgM positive and 17 (26%) were IgG positive. Moreover, for 44 of the 66 participants, simultaneous tests were carried out using a rapid test kit from a different manufacturer but without FDA-EUA and all the results completely matched with the FDA-EUA kit, except one case where the FDA-EUA kit showed positive for both IgG and IgM while the other kit was positive only for IgM. The 26% positive IgG indicates a high exposure rate for the hospital staff and patients and points to community transmission where the facility is situated. Hence, immediate activation of WHO guidelines for controlling community transmission is called for. These results can further serve as a pilot study to guide public health policies in response to COVID-19 pandemic in both the general population and in healthcare settings.
It is made available under a CC-BY-NC-ND 4.0 International license .
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20145441; this version posted July 24, 2020. The copyright holder for this preprint

Details

show
hide
Language(s):
 Dates: 2020-07-24
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: medRxiv: 2020.07.02.20145441
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: 2020.07.02.20145441
Source Genre: Commentary
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: - Sequence Number: - Start / End Page: - Identifier: medRxiv: 2020.07.02.20145441